News
Biological treatment is approved for severe eosinophilic asthma
BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6472 (Published 01 December 2016) Cite this as: BMJ 2016;355:i6472
- Susan Mayor
- London
Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1
The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list price of £840 (€992; $1046) for a once monthly dose—to a lower, but undisclosed, cost to the NHS.
Mepolizumab is a humanised monoclonal antibody that binds to interleukin …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.